Table 3.
Selection of clinical trials against cancer using siRNA drugs
| siRNA drug | Formulation | Target | Disease | Phase | Sponsor | References |
|---|---|---|---|---|---|---|
| CALAA-01 | Rondel® Nanoparticles (CD) | M2 subunit of ribonucleotide reductase (RRM2) |
Solid tumors | I | Calando Pharmaceuticals | 114 |
| Atu027 | siRNA with 2ʹ-O-Me and Cationic lipid | Protein Kinase N3 (PKN3) | Advanced solid tumors (metastatic pancreatic cancer) | I | Silence Therapeutics GmbH | 177 |
| ALN-RSV | Lipid nanoparticles | VEGF gene and kinesin spindle protein (KSP) gene | Solid tumors (Liver metastasis from colon cancer) | I | Alnylam pharmaceuticals | 178 |
| DCR-MYC | Lipid nanoparticles | Myc | Hepatocellular carcinoma | I | Dicerna pharmaceuticals | 179 |
| siRNAEphA2-DOPC | DOPC liposomes | Ephrin type-A receptor2 (EphA2) gene | Advanced cancers | I | M.D. Anderson Cancer center | 180 |
| siG12D-LODER | LODER® (Polymer) | KRAS (mutation G12D in KRAS oncogene) | Solid tumors (advanced pancreatic cancer) | II | Silenseed Ltd | 181 |
Abbreviations: 2ʹ-O-Me, 2ʹ-O-methyl-RNA units; CD, cyclodextrins; DOPC, 1,2-dioleoyl-snglycero-3-phosphatidylcholine neutral liposomes; LODER®, LOcal Drug EluteR; VEGF, vascular endothelial growth factor.